Find out how scientists are maximizing retinal organoid effectiveness to sustain critical retinal ganglion cells.

Two of Opus's seven gene therapy assets are in clinical trials, with additional programs expected to enter the clinic.

Has it ever happened that your 'cooler' sibling stole all your limelight? Well, that's exactly what retinal is doing to ...

Skincare enthusiasts are buzzing about Retinal, a potent Vitamin A derivative that's faster and more effective than ...

The blood-brain and blood-retinal barriers are protective systems that prevent harmful substances from entering the brain and ...

Until now, it has been difficult to maintain retinal ganglion cells deep inside organoids over extended periods. The supply ...

RetinalGenix is developing a portfolio of non‑invasive imaging solutions, including a portable Retinal Imaging Screening Device and the RetinalCam remote monitoring system, designed for use without ...

The addition of RACI reflects AllyGPO and BioCareSD's continued growth in community retina, as practices seek support in ...

Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...

About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...